Trials / Completed
CompletedNCT02118532
The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Medtronic Endovascular · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm that the IN.PACT Admiral is safe and effective for the interventional treatment of new and non-stented restenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in Chinese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter | IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-08-01
- Completion
- 2016-09-01
- First posted
- 2014-04-21
- Last updated
- 2016-12-30
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02118532. Inclusion in this directory is not an endorsement.